bims-meract Biomed News
on Metabolic reprogramming and anti-cancer therapy
Issue of 2026–11–15
fourteen papers selected by
Andrea Morandi, Università degli Studi di Firenze



  1. Radiat Res. 2026 Feb 09. 205(2): 187-198
      Radiotherapy remains a standard treatment for prostate cancer (PCa), inducing tumor cell death and apoptosis. However, its efficacy depends on various factors, including tumor cell metabolism. In this study, we investigated whether alterations in proline metabolism influence the response of prostate cancer cells to radiation. The radiosensitivity of LNCaP and C4-2 cells after X-ray irradiation was assessed using colony formation and tumor-sphere assays, while Matrigel invasion assays evaluated in vitro cell invasion. We then examined the effect of radiation on proline dehydrogenase (PRODH) expression and MAPK/p-MAPK signaling via Western blotting. To further explore the role of proline metabolism in radiation response, we tested the impact of exogenous proline supplementation and PRODH knockdown on radiation efficacy in LNCaP and C4-2 cells using the same assays. Finally, in vivo validation was performed using xenograft tumor models in nude mice to determine how proline and PRODH modulation influences radiation outcomes. Our results demonstrated that X-ray irradiation significantly inhibited prostate cancer cell growth and invasion. However, this effect was attenuated by exogenous proline supplementation. Following irradiation, proline dehydrogenase (PRODH) expression was upregulated, while phosphorylated MAPK (p-MAPK) levels were downregulated. Notably, the suppressive effect of proline on radiation efficacy was abolished upon PRODH knockdown, suggesting a key role for proline metabolism in radiation response. In vivo studies further supported these findings: X-ray irradiation effectively suppressed tumor growth in xenograft mouse models, but this therapeutic effect was diminished when mice were treated with proline solution. These observations align with our in vitro data, reinforcing the modulatory role of proline metabolism in radiosensitivity. While radiotherapy demonstrates robust antitumor effects in prostate cancer, our findings reveal that proline metabolism significantly impairs radiation efficacy in both cellular and animal models.
    DOI:  https://doi.org/10.1667/RADE-24-00171.1
  2. Int J Mol Sci. 2026 Oct 25. pii: 9535. [Epub ahead of print]27(21):
      Ovarian cancer (OC) is often diagnosed at advanced stages, and resistance to platinum-based chemotherapy remains one of the leading causes of treatment failure. This resistance is sustained in part by metabolic plasticity, particularly through the de novo serine synthesis pathway (SSP), orchestrated by D-3-phosphoglycerate dehydrogenase (PHGDH), which diverts glycolytic carbon toward serine, glycine, and one-carbon (1C) units that fuel nucleotide biosynthesis, epigenetic regulation, and redox homeostasis. Elevated PHGDH expression in OC is associated with advanced International Federation of Gynecology and Obstetrics (FIGO) stage and poorer overall survival; conversely, a subset of tumors downregulates PHGDH at relapse and shifts toward NAD+-dependent pathways that sustain poly(ADP-ribose) polymerase (PARP) activity and DNA repair, creating a distinct therapeutic vulnerability. Rather than a contradiction, this bidirectional behavior reflects the metabolic plasticity through which OC adapts to treatment pressure. Therefore, this review analyzes the context-dependent role of PHGDH in OC, the mechanistic basis of divergent associations with therapy resistance, and the current status of pharmacological inhibitors. Preclinical evidence indicates that PHGDH inhibition with CBR-5884 increases oxidative stress, reduces stemness, and restores platinum sensitivity in PHGDH-high models. We further identify the relationship between PHGDH and radiotherapy response as an unexplored question in OC, despite evidence of SSP-dependent radioresistance in other tumor types. Together, these observations position PHGDH as an actionable, but biomarker-dependent, metabolic target in OC.
    Keywords:  PHGDH; metabolism; ovarian cancer; platinum-resistance
    DOI:  https://doi.org/10.3390/ijms27219535
  3. Nat Commun. 2026 10 13. pii: 11589. [Epub ahead of print]17(1):
      Nicotinamide adenine dinucleotide (NAD+) replenishment sensitizes tumors to immunotherapy. However, chemotherapy-induced NAD+ metabolic reprogramming remains poorly understood. Here, we show that chemotherapy induces a macrophage-dependent IL-1β inflammatory response and NAD+ metabolic reprogramming, thereby conferring chemoresistance via CD44. Mechanistically, IL-1β-induced NAD+ salvage cooperates with the clearance of nicotinamide (NAM), the physiological inhibitor of the NAD+-consuming enzymes sirtuins, to drive CD44-mediated chemoresistance by boosting the NAD+/NAM ratio for sirtuin activation. NAM phosphoribosyltransferase (NAMPT)-mediated NAD+ salvage recycles NAD+ from NAM and further triggers serine biosynthesis, ultimately supporting NAM N-methyltransferase (NNMT)-mediated NAM clearance. Importantly, NAMPT inhibition disrupts the NAD+/NAM ratio and mitigates CD44-mediated chemoresistance and NK cell dysfunction, ultimately enhancing the efficacy of chemoimmunotherapy when combined with IL-2 across multiple preclinical models of solid tumors. Thus, our findings underscore the NAD+/NAM ratio as a metabolic therapeutic target for enhancing chemotherapy and NK cell-based chemoimmunotherapy efficacy.
    DOI:  https://doi.org/10.1038/s41467-026-78491-z
  4. Apoptosis. 2026 Nov 11. pii: 260. [Epub ahead of print]31(12):
       BACKGROUND: Hyperactivation of the antioxidant transcription factor Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) strongly correlates with tumor progression and poor prognosis in aggressive breast cancers. While Nrf2 is known to influence tumor metabolism, the precise molecular mechanism by which it orchestrates "metabolic plasticity", the ability to flexibly fulfill immense bioenergetic demands, remains largely elusive.
    METHODS AND RESULTS: Integrating clinical dataset analysis with in vitro genetic manipulation (MCF7 and MDA-MB-231), we confirmed Nrf2 as a core driver of breast cancer tumorigenesis. Metabolic profiling revealed that Nrf2 confers robust metabolic plasticity by concurrently upregulating both oxidative phosphorylation (OXPHOS) and glycolysis, resulting in an ATP production surge. Mechanistically, Nrf2 upregulates the expression of SIRT1, which serves as an indispensable hub for this dual metabolic enhancement. Pharmacological inhibition (using NAM or EX527) or genetic knockdown of SIRT1 effectively dismantled the Nrf2-driven metabolic advantage, drastically reducing ATP levels and suppressing colony formation. Furthermore, we uncovered an additive cytotoxic effect where combining SIRT1 inhibition with oxidative stress (H2O2) severely impaired the bioenergetic reserve and disrupted redox balance, leading to a marked suppression of cancer cell survival and clonogenic capacity.
    CONCLUSION: Our findings identify the Nrf2-SIRT1 axis as a master coordinator of metabolic plasticity in breast cancer. Repurposing SIRT1 inhibitors to disrupt this bioenergetic adaptation provides a potential, mechanism-guided rationale to sensitize therapy-resistant and Nrf2-hyperactivated breast cancer cells to oxidative stress in preclinical models.
    Keywords:  Breast cancer; Energy metabolism; Mitochondria; Nrf2; Oxidative stress; SIRT1
    DOI:  https://doi.org/10.1007/s10495-026-02471-3
  5. Cancer Cell Int. 2026 Nov 13. pii: 361. [Epub ahead of print]26(1):
       BACKGROUND: The Warburg effect, characterized by enhanced glycolysis and lactate production, is a universal feature of cancer cells, even under normoxic conditions. The resulting extracellular acidification and intracellular alkalization create a selective vulnerability that is absent in normal tissues. We previously developed the Warburg Trap (WT) approach, which exploits this vulnerability by combining inhibitors of mitochondrial complex I with H+-ionophores to collapse pH homeostasis and energy balance, thereby inducing cancer-specific cell death. Given that the bone marrow microenvironment in multiple myeloma (MM) is markedly acidic (pH 6.7-6.8 compared to ~ 7.4 in normal bone marrow), we hypothesized that MM cells would be highly sensitive to WT treatment.
    METHODS: The effects of individual WT drugs and drug combinations on three human myeloma cell lines (hMCLs), primary MM cells and one non-neoplastic human osteoblast-like cell line (hOBs) were analyzed in vitro. To evaluate the cytotoxic effects, the IC50 values of the drugs were calculated, and the Zero Interaction Potency (ZIP) model was used to identify possible synergies. Cell viability, intracellular pH values (pHi), the invasive potential, apoptosis induction, glucose uptake, ATP levels, mitochondrial depolarization and glucose transporter expression were analyzed using fluorescence microscopy, flow cytometry, RT-qPCR analysis and various in vitro assays.
    RESULTS: Combinations of the mitochondrial complex I inhibitors metformin (Me) and fenofibrate (Fe) with one of the H+-ionophores drotaverine (Dro) or monensin (Mo) significantly induced apoptosis in hMCLs and primary MM cells, while hOBs remained unaffected. The triple medication regimen exhibited a clear synergistic effect compared to monotherapy. Mechanistic analyses revealed a pronounced drop in pHi, disruption of glucose metabolism, depletion of ATP and loss of mitochondrial potential in response to these drugs. Furthermore, the WT drugs suppressed the invasive potential of MM cells and induced the upregulation of the stress-associated gene DDIT3 and the encoded CHOP protein. RT-qPCR profiling of solute carrier family 2 A (SLC2A) genes, encoding glucose transporters (GLUTs) revealed that SLC2A1, SLC2A8 and SLC2A9 were the most abundant transcripts in MM cells, with SLC2A8 showing the most pronounced difference between MM cells and non-neoplastic hOBs. Additionally, SLC2A8 expression associated with the observed WT-drug sensitivity of the analyzed cell lines.
    Keywords:  Cancer metabolism; Metabolic cancer therapy, Metformin; Multiple myeloma; Warburg Trap; Warburg effect
    DOI:  https://doi.org/10.1186/s12935-026-04504-y
  6. Mol Cell. 2026 Nov 12. pii: S1097-2765(26)00742-2. [Epub ahead of print]
      Perturbed glucose homeostasis is a hallmark of metabolic disease and cancer, and cellular responses to excess glucose are tightly controlled. We report here a lysosomal glucose sensing axis linking the transporter GLUT1 with the lysosomal protein DRAM1. Pathophysiological glucose induces DRAM1 via the MLX/ChREBP transcriptional complex. DRAM1 then binds newly synthesized GLUT1 and promotes its traffic to lysosomes without degradation, reducing surface GLUT1 and acting as a reversible brake on glucose entry. Hexokinase or glucose-6-phosphate (G6P) dehydrogenase disruption weakens DRAM1-GLUT1 complex formation, whereas nicotinamide adenine dinucleotide phosphate(NADPH) oxidase (NOX) inhibition enhances assembly, implicating NADPH as a key metabolic signal downstream of elevated glucose. Sequestration of GLUT1 suppresses glucose uptake and glycolysis and rewires metabolism toward glutamine anaplerosis, creating vulnerability to glutaminase (GLS) inhibition. In vivo, Dram1-/- tumors display a glycolytic metabolite profile, consistent with loss of this brake. Together, these data define an mTORC1- and AMPK-independent lysosomal mechanism that protects metabolic homeostasis under hyperglycemic conditions.
    Keywords:  DRAM1; GLUT1; NADPH; glucose sensing; glutamine anaplerosis; hyperglycemia; lysosomes; metabolism
    DOI:  https://doi.org/10.1016/j.molcel.2026.10.022
  7. Acta Biochim Biophys Sin (Shanghai). 2026 Nov 25. 58(11): 2486-2502
      The occurrence of resistance to sorafenib, a first-line treatment for hepatocellular carcinoma (HCC), significantly limits its clinical efficacy. Therefore, investigating the potential mechanism of sorafenib resistance in HCC is highly important for developing HCC treatment strategies. In the present study, we identify that SPP1 (encoding osteopontin; OPN) is significantly elevated in sorafenib-resistant HCC. Furthermore, the upregulation of SPP1 is related to vascular invasion, advanced disease stage and poor prognosis in HCC patients. As the IC 50 value of sorafenib increases in HepG2 cells, the SPP1 protein secreted by the cells is significantly upregulated, which subsequently facilitates the proliferation of human umbilical vein endothelial cells (HUVECs) and resistance to sorafenib. Further studies reveal that SPP1 induces resistance to sorafenib in HepG2 cells by upregulating glycolysis in HUVECs and further producing lactate. Mechanistically, SPP1 increases the expressions of the glucose transporter GLUT1 and the key glycolytic enzymes PFK1 and PKM2 in HUVECs, resulting in lactate accumulation, which in turn promotes the phosphorylation levels of BRAF and ERK as well as HIF-1α expression in HepG2 cells, leading to sorafenib resistance in HCC. Notably, SPP1 silencing can inhibit the proliferation and invasion of sorafenib-resistant HepG2 cells both in vitro and in vivo . Importantly, lactate derived from HUVECs plays a more dominant role in sorafenib resistance than does SPP1 in HepG2 cells. In summary, SPP1 enhances sorafenib resistance in HepG2 cells through promoting aerobic glycolysis in HUVECs, suggesting that the SPP1-aerobic glycolysis axis might be a prognostic biomarker as well as a potential therapeutic target for sorafenib-resistant HCC.
    DOI:  https://doi.org/10.3724/abbs.2025245
  8. J Pharmacol Sci. 2026 Dec;pii: S1347-8613(26)00055-1. [Epub ahead of print]162(4): 268-280
      Non-small-cell lung cancer (NSCLC) is a major type of lung cancer, accounting for 85% of lung cancer cases. Statins are cholesterol-lowering drugs that exert anticancer effects by inhibiting HMG-CoA reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway, in multiple cancer types, including NSCLC. However, statin sensitivity varies among cancer cells, highlighting the need to identify the determinants of this variability. High basal expression and statin-induced upregulation of mevalonate pathway enzymes, including HMGCR, are associated with statin resistance in cancer cells. Given that the expression of mevalonate pathway enzymes is regulated by cholesterol, intracellular cholesterol status may influence statin sensitivity. Here, we demonstrated that cholesterol supplementation enhanced the growth-inhibitory effects of atorvastatin in NSCLC cells with an increase in fluorescence intensity of filipin, which binds to free cholesterol. In contrast, methyl-β-cyclodextrin, a cholesterol-depleting agent, attenuated the effects of atorvastatin with a slight decrease in filipin intensity. In addition, oxysterols, which are oxidized derivatives of cholesterol, enhanced the effects of atorvastatin without increasing the filipin intensity. Furthermore, the lysosomal cholesterol transport inhibitor U18666A attenuated the effects of atorvastatin, with an increase in filipin intensity. Our data suggested that quantitative and qualitative intracellular cholesterol status may regulate statin sensitivity in NSCLC cells.
    Keywords:  Cholesterol; Mevalonate pathway; Non-small-cell lung cancer; Oxysterol; Statin sensitivity
    DOI:  https://doi.org/10.1016/j.jphs.2026.09.005
  9. Biochem Pharmacol. 2026 Nov 07. pii: S0006-2952(26)00945-7. [Epub ahead of print]254(Pt 4): 118602
      Gemcitabine (GEM) resistance poses a significant challenge to the survival of patients with pancreatic cancer. A key mechanism underlying this resistance is the aberrant activation of the pentose phosphate pathway (PPP), which leads to increased levels of deoxycytidine triphosphate (dCTP) and competitively inhibits the incorporation of gemcitabine into DNA. However, the upstream regulator of PPP hyperactivation in GEM-resistant pancreatic cancer remains unclear. Here, we reported that SP1-CD44 signaling modulated gemcitabine sensitivity and PPP-associated metabolic parameters in pancreatic cancer. Mechanistically, knockdown of SP1 reduced G6PDH activity and decreased the levels of NADPH and G6P, whereas overexpression of CD44 resulted in the opposite effects. Functionally, inhibition of this axis increased the sensitivity of pancreatic cancer cells to GEM. Given its therapeutic potential, we sought to identify candidate SP1-targeting compounds with the potential to enhance gemcitabine sensitivity. A small-scale screen of known SP1 inhibitors revealed mithramycin A (MIT) to be effective, but its significant toxicity is well documented. To identify safer alternatives, we screened anti‑pancreatic cancer natural products in the natural product library of our laboratory, guided by computer-aided drug discovery. Molecular docking and molecular dynamics simulations suggested that arenobufagin (ABA) and bufalin (BA) may bind to SP1. In summary, our findings support a role for the SP1-CD44 axis in gemcitabine resistance and suggest that enhanced PPP-associated metabolic activity may contribute to this phenotype. Furthermore, we identified ABA and BA as candidate compounds that increase gemcitabine-associated apoptosis in pancreatic cancer cells, warranting further investigation of their potential as SP1-targeting agents.
    Keywords:  Drug discovery; Gemcitabine resistance; Pancreatic cancer; Pentose phosphate pathway; SP1
    DOI:  https://doi.org/10.1016/j.bcp.2026.118602
  10. Adv Sci (Weinh). 2026 Nov 09. pii: e78669. [Epub ahead of print]
      Mitochondrial metabolism-dependent cuproptosis has emerged as a promising anticancer modality, yet its efficacy is constrained by the hypoxic and glycolysis-dominant tumor microenvironment that suppresses oxidative phosphorylation (OXPHOS). Strategies that simultaneously overcome hypoxia and mitochondrial metabolic resistance remain underexplored. Herein, we report a bioengineered mitochondrial respiration-mimetic nanoplatform (TC@OMG) that renews tumor mitochondrial metabolism to enhance cuproptosis. TC@OMG integrates a copper-based metal-organic framework co-loaded with glucose oxidase and a lactate dehydrogenase inhibitor, and is cloaked with a hybrid membrane derived from tumor cells and plant thylakoids, enabling tumor targeting and photosynthetic oxygen generation. Mechanistically, photo-triggered TC@OMG couples hypoxia alleviation with glycolysis inhibition to enforce a metabolic shift toward mitochondrial OXPHOS, thereby sensitizing tumor cells to cuproptosis. Concurrently, its microenvironment-responsive copper release and glutathione depletion disrupt mitochondrial Fe-S cluster homeostasis and induce aggregation of lipoylated proteins, ultimately promoting cuproptotic cell death. In vivo, photo-triggered TC@OMG achieves efficient tumor targeting, hypoxia relieving, and tumor inhibiting effects across multiple melanoma models, including subcutaneous, metastatic, and intraocular tumors. Collectively, this work bioengineered a respiration-mimetic nanotherapeutic strategy that integrates mitochondrial metabolic reprogramming with copper-dependent cell death, providing a generalizable strategy for overcoming mitochondrial metabolic resistance in cancer therapy.
    Keywords:  cuproptosis; hybrid‐membrane; melanoma; mitochondrial metabolism; tumor targeting
    DOI:  https://doi.org/10.1002/advs.78669
  11. Elife. 2026 Nov 10. pii: RP110991. [Epub ahead of print]15
      Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
    Keywords:  HT29 cells; RKO cells; biochemistry; cancer biology; chemical biology; colon organoids; human; mouse
    DOI:  https://doi.org/10.7554/eLife.110991
  12. Cancer Lett. 2026 Nov 12. pii: S0304-3835(26)00736-6. [Epub ahead of print] 218972
      Colorectal cancer (CRC) is a highly heterogeneous malignancy. Although surgery-based multimodal therapy provides durable benefits for a subset of patients with localized disease, a considerable proportion of patients still experience recurrence or progression post-treatment. Delineating the molecular mechanisms underlying CRC progression and chemoresistance is imperative for identifying therapeutic targets and thereby improving treatment outcomes. Using single-cell RNA sequencing (scRNA-seq), we identified C-C motif chemokine ligand 7 (CCL7) as a key mediator of intercellular communication between tumor-associated macrophages (TAMs) and CRC cells within the tumor microenvironment (TME). TAMs express and secrete high levels of CCL7, which reprograms lipid metabolism in CRC cells, induces the accumulation of lipid droplets (LDs), and markedly promotes CRC cell proliferation and chemoresistance. Elevated CCL7 expression is associated with poor prognosis in patients with CRC. Bulk RNA-seq revealed that CCL7 markedly upregulates the expression of the transcription factor BATF3. Integrating CUT&Tag profiling, HOMER de novo/known motif enrichment analysis, FIMO prediction, co-immunoprecipitation (Co-IP), and dual-luciferase reporter assays, we demonstrated that BATF3 interacts with JunD to synergistically activate the USP22 promoter, thereby upregulating USP22 expression. Furthermore, USP22 deubiquitinates and stabilizes DGAT2, thereby promoting LD accumulation and lipid metabolic reprogramming, which accelerates malignant progression and acquired chemoresistance in CRC. By dissecting the intricate crosstalk within the CRC microenvironment, we elucidated the molecular cascade through which the CCL7-dependent BATF3/USP22/DGAT2 axis drives tumor progression and chemoresistance. Targeting this axis may block lipid metabolic reprogramming and thereby curb these malignant phenotypes, highlighting a promising therapeutic strategy for CRC.
    Keywords:  CCL7; Colorectal cancer; Lipid metabolic reprogramming; Tumor progression; Tumor-associated macrophages
    DOI:  https://doi.org/10.1016/j.canlet.2026.218972
  13. Cell Death Discov. 2026 Aug 13. pii: 449. [Epub ahead of print]12(1):
      The majority of patients with colorectal cancer (CRC) fail to respond to anti-PD-1/PD-L1 immunotherapy, highlighting an urgent need for alternative immunotherapeutic targets. The immunosuppressive ligand CD155 potently dampens natural killer (NK) cell cytotoxicity via inhibitory receptors, but how CRC cells sustain high CD155 surface levels remains elusive. Here, we identify aberrant CD155 N-glycosylation as a critical driver of CRC immune evasion. We find that the glycosyltransferase STT3A contributes to N-glycosylation of CD155. This modification is essential for maintaining CD155 protein stability, thereby sustaining its surface expression to suppress NK cell-mediated antitumor immunity. Consistent with a role for N-glycosylation in maintaining CD155 expression, pharmacological inhibition of oligosaccharyltransferase activity with NGI-1 promotes CD155 turnover, effectively abrogating its immunosuppressive function and enhancing NK cell-mediated tumor clearance in vivo. Collectively, these findings implicate the STT3A-CD155 glycosylation axis as a therapeutic vulnerability, providing a mechanistic rationale for reprogramming the immunosuppressive CRC microenvironment.
    DOI:  https://doi.org/10.1038/s41420-026-03302-9
  14. Cell Death Dis. 2026 Aug 13. pii: 956. [Epub ahead of print]17(1):
      Transmembrane protein 189 (TMEM189), also known as plasmanylethanolamine desaturase 1 (PEDS1), is involved in plasmalogen biosynthesis, phospholipid metabolism, ferroptosis, and autophagy. However, whether TMEM189/PEDS1 regulates macrophages and disease-related inflammatory responses remains unclear. Here, we for the first time investigated the contribution of TMEM189/PEDS1 to macrophage activation and progression of metabolic dysfunction-associated steatohepatitis (MASH). Experimental data demonstrated that TMEM189 is highly expressed in macrophages, and its inactivation promotes M1 macrophage polarization and increases lipid loading in co-cultured hepatocytes. Loss of Tmem189 in myeloid cells results in a selective increase in the population and activation of monocyte-derived macrophages (MDMs) in the liver, which exacerbates hepatic steatosis, inflammatory damage, and fibrosis in diet-induced MASH mice. The restoration of Tmem189 expression in hepatic macrophages significantly attenuates MASH-related phenotypes. Mechanistically, TMEM189 interacts with fatty acid synthase (FASN), negatively regulates its expression and pro-inflammatory response in macrophages. Further studies revealed that TMEM189 deletion enhances FASN-promoted NLRP3 palmitoylation and its activation, leading to increased IL-1β production, which in turn further accelerates MASH progression. Our findings provide important evidence supporting the critical regulatory role of TMEM189-FASN signaling in liver macrophage activation and MASH progression, which may represent a potential therapeutic target for MASH treatment.
    DOI:  https://doi.org/10.1038/s41419-026-09145-7